Nationwide Fund Advisors’s Tempest Therapeutics TPST Stock Holding History

Nationwide Fund Advisors’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-7	Closed	-$38K	–	3262
2017 Q1	$38K	Hold	7	–	–	﹤0.01%	3026
2016 Q4	$31K	Hold	7	–	–	﹤0.01%	3058
2016 Q3	$144K	Hold	7	–	–	﹤0.01%	2777
2016 Q2	$105K	Buy	7 +2	+40%	+$45.7K	﹤0.01%	2896
2016 Q1	$144K	Hold	5	–	–	﹤0.01%	2679
2015 Q4	$149K	Hold	5	–	–	﹤0.01%	2688
2015 Q3	$129K	Hold	5	–	–	﹤0.01%	2800
2015 Q2	$440K	Buy	5 +1	+25%	+$91.6K	﹤0.01%	2319
2015 Q1	$436K	Hold	4	–	–	﹤0.01%	2303
2014 Q4	$516K	Hold	4	–	–	﹤0.01%	2166
2014 Q3	$191K	Hold	4	–	–	﹤0.01%	2714
2014 Q2	$104K	Buy	4 +1	+33%	+$23.6K	﹤0.01%	3015
2014 Q1	$71K	Buy	3 +1	+50%	+$28.3K	﹤0.01%	2824
2013 Q4	$65K	Hold	2	–	–	﹤0.01%	3035
2013 Q3	$70K	Buy	2 +1	+100%	+$35.5K	﹤0.01%	3011
2013 Q2	$39K	Buy	+1	New	+$37.6K	﹤0.01%	3000

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nationwide Fund Advisors's TPST Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Tempest Therapeutics (TPST) in Q2 2017, closing a stake of 7 shares — an estimated $38K sold.

Nationwide Fund Advisors first reported a position in TPST in Q2 2013 and held it in 16 quarters. The position peaked at $516K in Q4 2014. 54 funds tracked by Wall St. Rank hold TPST as of Q2 2017.

Nationwide Fund Advisors reported no remaining Tempest Therapeutics position as of Q2 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 7 Tempest Therapeutics shares in Q2 2017, an estimated $38K.
Nationwide Fund Advisors first reported a position in Tempest Therapeutics in Q2 2013 and held it in 16 quarters.
Nationwide Fund Advisors's Tempest Therapeutics position peaked at $516K in Q4 2014.
54 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.